Despite this, MHC-II expression is a potent positive predictor of benefit from an anti PD1/PD-L1 addition in the neoadjuvant setting in both TNBC [82,83] and HR+/HER2− BC patients [82]. The gene discussed is CD274; the disease is breast cancer.